Northwestern Mutual Wealth Management Co. Increases Holdings in Insulet Co. (NASDAQ:PODD)

Northwestern Mutual Wealth Management Co. increased its stake in Insulet Co. (NASDAQ:PODD) by 10.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,000 shares of the medical instruments supplier’s stock after acquiring an additional 95 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Insulet were worth $202,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Insulet by 1.1% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock worth $1,264,000 after purchasing an additional 66 shares during the period. UMB Bank n.a. raised its stake in shares of Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares during the period. Moody National Bank Trust Division lifted its holdings in shares of Insulet by 2.6% in the 1st quarter. Moody National Bank Trust Division now owns 3,439 shares of the medical instruments supplier’s stock worth $589,000 after acquiring an additional 87 shares during the last quarter. Motley Fool Asset Management LLC boosted its stake in shares of Insulet by 7.1% during the 1st quarter. Motley Fool Asset Management LLC now owns 1,397 shares of the medical instruments supplier’s stock worth $239,000 after purchasing an additional 93 shares during the period. Finally, State of Michigan Retirement System grew its holdings in Insulet by 0.5% during the 2nd quarter. State of Michigan Retirement System now owns 19,200 shares of the medical instruments supplier’s stock valued at $3,875,000 after purchasing an additional 100 shares during the last quarter.

Insulet Stock Down 0.3 %

Shares of NASDAQ PODD opened at $231.20 on Friday. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $243.98. The stock’s fifty day simple moving average is $213.47 and its two-hundred day simple moving average is $194.17. The stock has a market capitalization of $16.19 billion, a PE ratio of 70.06, a price-to-earnings-growth ratio of 4.35 and a beta of 1.21. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). The company had revenue of $488.50 million during the quarter, compared to analysts’ expectations of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. Insulet’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.38 EPS. As a group, analysts expect that Insulet Co. will post 3.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on PODD. Piper Sandler raised their price objective on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Citigroup boosted their price objective on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Canaccord Genuity Group increased their target price on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. UBS Group boosted their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Finally, BTIG Research reduced their price target on shares of Insulet from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $234.60.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.